Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authoridAkin Telli, Tugba/0000-0001-6535-6030
dc.authoridSAKIN, Abdullah/0000-0003-2538-8569
dc.authoridGursoy, Pinar/0000-0003-1392-6753
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.authoridGOKER, ERDEM/0000-0001-6180-713X
dc.authorwosidErdogan, Atike Pinar/AFC-3012-2022
dc.authorwosidCelik, Emir/GRF-6617-2022
dc.authorwosidAkin Telli, Tugba/GSE-4006-2022
dc.contributor.authorGürsoy, Pınar
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorErdem, Dilek
dc.contributor.authorGöker, Erdem
dc.contributor.authorÇelik, Emir
dc.contributor.authorDemirci, Nebi Serkan
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorÇavdar, Eyyüp
dc.date.accessioned2023-04-20T08:01:19Z
dc.date.available2023-04-20T08:01:19Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.description.abstractObjectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study. Results EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p = 0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p = 0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically different than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p = 0.323). Conclusion In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options.
dc.identifier.doi10.1007/s00432-022-03984-5
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.pmid35381885
dc.identifier.scopus2-s2.0-85127494466
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1007/s00432-022-03984-5
dc.identifier.urihttps://hdl.handle.net/20.500.11776/10868
dc.identifier.wosWOS:000779481900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÇavdar, Eyyüp
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofJournal of Cancer Research and Clinical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectExon 18
dc.subjectExon 20
dc.subjectErlotinib
dc.subjectAfatinib
dc.subjectNsclc
dc.subjectGrowth-Factor Receptor
dc.subjectTyrosine Kinase Inhibitor
dc.subject1st-Line Treatment
dc.subjectOpen-Label
dc.subjectMulticenter
dc.subjectEfficacy
dc.subjectChemotherapy
dc.titleReal-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10868.pdf
Boyut:
654.62 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu